Collect Product
Product Details
- ProductSizeAmountCellectra™ Human CD8 NanoSort Microbeads, Research grade2 mLFor 10⁹ total cells
Product Show
This product is compatible with mainstream automated cell processing instruments and commercially available column-based (M/D/L) magnetic separation systems.
Features
- High Safety
- Raw Material Safety: The conjugated antibodies are recombinant antibodies, avoiding contamination from animal-derived viruses and exogenous factor pollutants. Medical-grade nanoparticles with dextran matrix coating - high biocompatibility, biodegradable.
- Supply Chain Safety: Highly integrated autonomous platforms for nano-magnetic beads and single B-cell antibody.
- Process Safety : AOF production process prevents exogenous factor contamination, with rigorous quality control ensuring product safety.
- High Sorting Purity
- Conjugated antibodies are derived from a single B-cell antibody development platform, featuring optimized antibody epitopes.
- Nanoscale superparamagnetic beads enable efficient and gentle cell sorting.
- Long-Term Stability
- Stable for 24 months at -20 °C or below.
- High Safety
Product Description
Cellectra™ Human CD8 NanoSort Microbeads are dextran-coated superparamagnetic nanoparticles conjugated with recombinant monoclonal antibodies specific to human CD8. They are especially designed for positive or negative selection of CD8+ cells.
The beads are manufactured under sterile ISO 5 conditions with no animal- or human-derived components. Each batch undergoes rigorous quality control, including sterility, endotoxin, and functional validation.Application
Cellectra™ Human CD8 NanoSort Microbeads are designed for the positive selection or negative selection of human cytotoxic CD8+ T cells from fresh or frozen human peripheral blood mononuclear cells (PBMCs). The CD8 antigen forms a complex together with the T cell receptor and acts as an accessory molecule in the recognition of MHC class I/peptide complexes by the TCR heterodimer on CD8+ cytotoxic T cells. It is predominantly expressed on the surface of cytotoxic T cells. The magnetic nBeads are conjugated with monoclonal antibodies targeting human CD8 protein, enabling CD8+ cells to be labeled with the specific antibodies and magnetic particles, and separated using the separation columns and magnets.
Storage
For long term storage, the product should be stored in liquid state at -20°C or below. Stability upon receipt: Stable for 24 months at -20 °C or below; Stable for 9 months at 2-8 °C under sterile conditions.
Please protect from light and avoid repeated freeze-thaw cycles.
Sterility
Negative
Endotoxin
Less than 2 EU per mL by the LAL method / rFC method.
Mycoplasma
Negative
Important Note
This product is for research use only and not intended for therapeutic or in vivo diagnostic use.
Formulation
Supplied in PBS buffer containing EDTA, rHSA and Poloxamer 188.
ACRO Quality Management System
Kunden haben auch angesehen
Data Display
Application Data
Superior Cell Separation Performance
Separation performance was evaluated using samples containing 1×10⁷ human PBMCs, processed with CD8 microbeads from Acro, Company M, or Company T at recommended dosages. Positive and negative fractions were collected, and 1×10⁶ cells from each fraction were immunostained with PE-conjugated anti-human CD8 antibody and 7-AAD, followed by flow cytometric analysis. Data indicated that Acro microbeads achieved a final purity of 98% (baseline: 27.15%), with a target cell residue of only 1.69% in the negative fraction. These findings validate outstanding separation performance, confirming an optimal balance of purity and recovery relative to competitor benchmarks.
Comparison of Cell Separation Performances
Isolation efficacy was validated using samples containing 1×10⁷ human PBMCs processed with the recommended dosage of Cellectra™ Human CD8 NanoSort Microbeads, in parallel with product from Company M and Company T. Comparative analysis demonstrated that Acro NanoSort Microbeads achieved higher cell recovery rates than Company M/T, while purity and cell viability were comparable to Company M and superior to Company T.
Cell Separation Performances of Different Donors
The separation performances of human PBMCs exhibited minor inter-donor variability, yet consistently maintained high purity and cell recovery across all donors (Routinely tested).
Cell Separation Performances after Freeze-Thawing and Accelerated Aging at 37℃
Freeze-thaw stability was verified by subjecting the microbeads to 2–3 cycles prior to separation testing. Comparative analysis against the standard batch confirmed that purity and cell recovery were maintained at baseline specifications, demonstrating robust stability. To ensure prolonged shelf life, storage at -20°C or below is recommended upon receipt (however, repeated freeze-thaw cycles are not advised for routine operational use).
Accelerated aging studies were conducted at 37°C to evaluate long-term stability profiles. Following 7 and 14-day incubation periods, the microbeads sustained high purity and cell recovery performance during PBMC separation. These data substantiate product stability and validate the established shelf-life specifications.
Batch-to-Batch Consistency
Manufacturing reproducibility was verified by conjugating three batches of CD8 NanoSort Microbeads with three corresponding batches of synthesized magnetic beads. Performance testing for human PBMC separation was conducted without dose adjustment; final dosage optimization will be completed during the pre-launch phase. Data indicates that all batches achieved consistent high purity and recovery, establishing reliable batch-to-batch consistency.
User Reviews Publish Comment
Frontier Progress
Drug Development Progress- English Name：
Cluster of differentiation 8
- Category：
- Listed Drugs Count：
0 Details
- Clinical Drugs Count：
18 Details
- Highest R&D Stage：
Phase 3 Clinical
Contact Us
Drug Candidate Licensing
